Citius Pharmaceuticals Stock (NASDAQ: CTXR)

Citius Pharmaceuticals

CITIUS PHARMACEUTICALS INC

Citius Pharma

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals Inc

Earnings

Small Cap

Press Releases

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch

Offerings

Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

News

Contracts

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

Citius Pharmaceuticals (NASDAQ: CTXR) Eyes $400M Market Opportunity with LYMPHIR Launch

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch

Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

CTOR

CTXR

AN2 Therapeutics

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Aytu BioPharma

CalciMedica

Cingulate

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Curanex Pharmaceuticals Inc - Common Stock

Curanex Pharmaceuticals

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Enveric Biosciences

Grace Therapeutics

Hoth Therapeutics

IGC Pharma

Iterum Therapeutics

Incannex Healthcare

Lexaria Bioscience

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

Pulmatrix

PolyPid

Rafael Holdings, Inc. Class B Common Stock

Rafael Holdings

SCYNEXIS

SenesTech

Traws Pharma

Tvardi Therapeutics

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

D. Boral Capital

HC Wainwright & Co.

EF Hutton

Screenshot 2024-08-06 at 7.17.40 PM

Biotech

General

TENK

Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology

Screenshot 2024-07-29 at 8.39.42 PM

From fighting cancer to treating bloodstream infections, Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is busy trying to solve some of the world&#39;s ills. That&#39;s picking up steam with two of its lead products close to commercialization. 

Citius Pharmaceuticals Nears Market Breakthrough With Two Leading Products

Screenshot 2024-07-24 at 5.43.01 PM

Interview

This Pharma Company Is Preparing To Launch Its Lead Candidate

Screenshot 2024-04-17 at 5.34.28 PM

Citius Pharmaceuticals (NASDAQ: CTXR) Advances Oncology Asset, Paving Way For Spin Out Of Advanced T-cell Lymphoma Treatment

Comments

Citius Pharmaceuticals

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL